Enrollment is now ongoing in a first-in-human clinical trial testing EPI-321, a therapy designed to target the underlying ...

If you're on the hunt for a holy grail product that will have you 'waking up looking younger', shoppers may have found just ...

People who ate more typical home-cooked meals lost twice the weight of people eating ultraprocessed foods that met healthy ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business ...

However, children treated with Tamiflu had about a 50% reduction in these problems, researchers found. Further, healthy kids who received Tamiflu to protect them against flu developed neurological and ...

TUESDAY, Aug. 5, 2025 (HealthDay News) — A large new study will follow the health and well-being of thousands of transgender ...

Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow disability progression.

Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel embolic system.

A study found neurofilament light chain at high levels in the blood and CSF of MS patients, suggesting its potential as a ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, discusses how real-time data access is helping biotechs accelerate trial timelines, ensure ...